Effects of edaravone injection combined with Rho kinase inhibitor on neurological function and serum ENA-78, HMGB1 levels in patients with acute cerebral infarction

Abstract

Objective To investigate the effects of edaravone injection combined with Rho kinase inhibitor fasudil on neurological function and serum levels of neutrophil activating peptide 78 (ENA-78) and high mobility group protein 1 (HMGB1) in patients with acute cerebral infarction. Methods Eighty-six patients with acute cerebral infarction in the Second People’s Hospital of Datong from December 2015 to March 2018 were enrolled. The patients were randomly divided into two groups, with 43 cases in each group. Edaravone was used in the control group, and the study group was treated with Rho kinase inhibitor (fasudil) on the basis of the treatment in the control group, and both the two groups were treated for 2 weeks. The daily living ability (BI) and neurological deficit (NIHSS) scores, clinical efficacy, serum ENA-78 and HMGB1 levels, nerve growth factor (NGF), brain-derived neurotrophic factor (BDNF) and the incidences of adverse reactions were compared. Results After treatment, the NIHSS and BI scores of the two groups were improved in comparison with those before treatment, and the BI score of the study group was higher than that of the control group, and the NIHSS score was lower than that of the control group (P 0.05). Conclusions Edaravone injection combined with Rho kinase inhibitor fasudil for acute cerebral infarction can effectively reduce the serum ENA-78 and HMGB1 levels, increase the BDNF and NGF levels, and promote the neurological function and daily living ability. It can improve the therapeutic effect of the disease, and does not increase the risk of adverse reactions, and has a certain degree of safety. Key words: Edaravone injection; Rho kinase inhibitor; Acute cerebral infarction; Neurological function; Neutrophil activating peptide 78; High mobility group protein 1